Brief: Context Therapeutics Doses First Patient In Phase 1 Clinical Trial Of Ct-95
09/04/2025 13:10
April 9 (Reuters) - Context Therapeutics Inc CNTX.O: CONTEXT THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1 CLINICAL TRIAL OF CT-95 CONTEXT THERAPEUTICS -ANTICIPATES SHARING INITIAL DATA FOR CT-95 PHASE 1 TRIAL IN MID-2026 Source text: ID:nGNX95Jt3c Further company coverage: CNTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Context Therapeutics
See all newsContext Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Context Therapeutics Q2 net loss widens on higher R&D costs
Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202